title: Donor-recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor.
abstract: Disparities at minor histocompatibility antigens (mHA) are thought to be responsible for acute graft-versus-host disease (aGVHD) in patients receiving bone marrow transplantation (BMT) from a human leucocyte antigen (HLA)-matched donor. Although some mHA have been identified in humans, their role in aGVHD has not. Patients (n = 150) receiving a BMT from an HLA-matched donor were investigated for a correlation between aGVHD and donor/recipient incompatibility for seven polymorphisms previously proposed for mHA (HA-1, H-Y, CD31-codon 125, CD31-codon 563, HPA-1, HPA-3 and HPA-5). Only mismatch at CD31-codon 563 predicted grade II-IV aGVHD. The risk derived from CD31-codon 563 mismatch was the same as that derived from the use of bone marrow from an unrelated donor. We suggest that donor/recipient compatibility at CD31-codon 563 should be added to HLA-typing for donor selection and/or adjustment of aGVHD prophylaxis.
authors.affiliation: Department of Internal Medicine, IRCCS San Matteo-University of Pavia, 27100 Pavia, Italy. c.balduini@smatteo.pv.it
authors.forename: C L
authors.initials: CL
authors.lastname: Balduini
authors.forename: F
authors.initials: F
authors.lastname: Frassoni
authors.forename: P
authors.initials: P
authors.lastname: Noris
authors.forename: C
authors.initials: C
authors.lastname: Klersy
authors.forename: A M
authors.initials: AM
authors.lastname: Iannone
authors.forename: A
authors.initials: A
authors.lastname: Bacigalupo
authors.forename: G
authors.initials: G
authors.lastname: Giorgiani
authors.forename: M
authors.initials: M
authors.lastname: Di Pumpo
authors.forename: F
authors.initials: F
authors.lastname: Locatelli
mesh_terms: D000208:Acute Disease; D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology*; D006801:Humans; D007938:Leukemia / Q000276:immunology* / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000628:therapy; D007951:Leukemia, Myeloid / Q000276:immunology / Q000628:therapy; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015778:Minor Histocompatibility Antigens / Q000276:immunology*; D009190:Myelodysplastic Syndromes / Q000276:immunology* / Q000628:therapy; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000235:genetics*; D011110:Polymorphism, Genetic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000628:therapy; D014181:Transplantation Immunology; D014184:Transplantation, Homologous
chemical_list: D015778:Minor Histocompatibility Antigens; D019408:Platelet Endothelial Cell Adhesion Molecule-1